Ross Levine
Chief Scientific Officer · New York Presbyterian Hospital
Credentials: · · · · ·
History
PresentMSK Center for Hematologic Malignancies · New York Presbyterian Hospital
- 2002–2005
Dana-Farber Cancer Institute and was
- 1995–1999
Research
Review · Blood · 2017 · 4,728 citations
The landscape of somatic copy-number alteration across human cancers
Nature · 2010 · 3,217 citations
Blood · 2022 · 2,814 citations
103 papers · 33 as a fellow
- MT
67 papers
- RR
46 papers · 18 as a fellow
- DG
42 papers
- ES
41 papers
34 papers
28 papers
- SC
28 papers
Grants
- 2021–2031
The Memorial Sloan Kettering Cancer Center SPORE in Leukemia
National Cancer Institute · P50
Project lead · $2.6M · Sloan-Kettering Inst Can Research
- 2026–2031
Clonal Hematopoiesis as a Targetable Mechanism of Resistance to Therapy in Thyroid Cancer.
National Cancer Institute · R01
PI · $752.8K · Sloan-Kettering Inst Can Research
- 2017–2030
Synergistic Role of Signaling and Epigenetics in Leukemic Transformation
National Cancer Institute · R35
Contact PI · $11.4M · Sloan-Kettering Inst Can Research
- 2006–2028
Myeloproliferative Neoplasms-Research Consortium
National Cancer Institute · P01
Project lead · $3.6M · Icahn School of Medicine at Mount Sinai
Clinical trials
- 2011
Principal investigator · Completed
Eastern Cooperative Oncology Group